[go: up one dir, main page]

MX2022003010A - Tratamiento de la emr mediante cambio de terapia. - Google Patents

Tratamiento de la emr mediante cambio de terapia.

Info

Publication number
MX2022003010A
MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A
Authority
MX
Mexico
Prior art keywords
treatment
therapy
emr
change
ofatumumab
Prior art date
Application number
MX2022003010A
Other languages
English (en)
Inventor
Krishnan Ramanathan
Dieter Adrian Haering
Morten Bagger
Martin Merschhemke
Marina Ziehn
Ratnakar Pingili
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022003010(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022003010A publication Critical patent/MX2022003010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al anticuerpo monoclonal anti-CD20 ofatumumab para usarse en el tratamiento o la prevención de la esclerosis múltiple remitente, en donde el ofatumumab se utiliza en un paciente que ha sido tratado con una terapia modificadora de la enfermedad diferente a ofatumumab.
MX2022003010A 2019-09-11 2020-09-10 Tratamiento de la emr mediante cambio de terapia. MX2022003010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19196789 2019-09-11
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Publications (1)

Publication Number Publication Date
MX2022003010A true MX2022003010A (es) 2022-06-02

Family

ID=72709332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003010A MX2022003010A (es) 2019-09-11 2020-09-10 Tratamiento de la emr mediante cambio de terapia.

Country Status (15)

Country Link
US (1) US20220298253A1 (es)
EP (2) EP3864053B1 (es)
JP (1) JP7794735B2 (es)
KR (1) KR20220062025A (es)
CN (3) CN114401742B (es)
AU (1) AU2020344154A1 (es)
CA (1) CA3150947A1 (es)
DK (1) DK3864053T3 (es)
ES (1) ES2957112T3 (es)
FI (1) FI3864053T3 (es)
IL (1) IL290619A (es)
LT (1) LT3864053T (es)
MX (1) MX2022003010A (es)
SI (1) SI3864053T1 (es)
WO (1) WO2021048280A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313932A (en) 2016-08-15 2024-08-01 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
KR20220062027A (ko) * 2019-09-11 2022-05-13 노파르티스 아게 오파투무맙-치료된 환자에서의 다발성 경화증 이외의 병태의 관리
US20240228647A1 (en) * 2021-04-14 2024-07-11 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
IL313932A (en) 2016-08-15 2024-08-01 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab

Also Published As

Publication number Publication date
ES2957112T3 (es) 2024-01-11
FI3864053T3 (fi) 2023-09-13
EP3864053A1 (en) 2021-08-18
CN118436777A (zh) 2024-08-06
DK3864053T3 (da) 2023-09-11
WO2021048280A1 (en) 2021-03-18
CN114401742A (zh) 2022-04-26
EP3864053B1 (en) 2023-07-05
CN118403156A (zh) 2024-07-30
CA3150947A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
SI3864053T1 (sl) 2023-12-29
LT3864053T (lt) 2023-09-11
KR20220062025A (ko) 2022-05-13
EP4230655A2 (en) 2023-08-23
US20220298253A1 (en) 2022-09-22
AU2020344154A1 (en) 2022-04-07
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
CN114401742B (zh) 2024-05-24
IL290619A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX2021002322A (es) Nuevos metodos.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
MX2022000143A (es) Metodos novedosos.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
JOP20210050A1 (ar) معدلات تعبير pnpla3
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
CL2022000214A1 (es) Inhibidores de enzimas
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂